Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes

Giuseppe Biondi-Zoccai, Marzia Lotrionte, Pierfrancesco Agostoni, Antonio Abbate, Enrico Romagnoli, Giuseppe Sangiorgi, Dominick J. Angiolillo, Marco Valgimigli, Luca Testa, Fiorenzo Gaita, Imad Sheiban

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Background: Clopidogrel is beneficial after ACS. Recent data suggest the superiority of prasugrel or ticagrelor compared with clopidogrel. However, there is no comparison of prasugrel vs. ticagrelor. We performed an adjusted indirect meta-analysis comparing prasugrel vs. ticagrelor for acute coronary syndromes (ACSs). Methods: Randomized trials were searched in PubMed. The primary end-point was the composite of death, myocardial infarction (MI) or stroke. Odds ratios (OR) were computed (95% confidence intervals). Results: Three trial (32,893) patients were included. Overall, either prasugrel or ticagrelor appeared significantly superior to clopidogrel for the 12-month risk of death, MI or stroke (OR = 0.83 [0.77-0.89], p <0.001), death (OR = 0.83 [0.74-0.93], p = 0.001), MI (OR = 0.79 [0.73-0.86], p <0.001), and stent thrombosis (OR = 0.61 [0.51-0.74], p <0.001), without any significant difference in stroke or major bleeding (both p > 0.05), despite more frequent drug discontinuation (OR = 1.12 [1.05-1.19], p <0.001). Head-to-head comparison of prasugrel vs. ticagrelor showed no significant differences in overall death, MI, stroke, or their composite (all p > 0.05). Prasugrel was associated with a significantly lower risk of stent thrombosis (OR = 0.64 [0.43-0.93], p = 0.020). Ticagrelor was associated with a significantly lower risk of any major bleeding (OR = 1.43 [1.10-1.85], p = 0.007), and major bleeding associated with bypass grafting (OR = 4.30 [1.73-10.6], p = 0.002). However, the more clinically relevant risk of major bleeding not related to bypass surgery was similar with either prasugrel or ticagrelor (OR = 1.06 [0.77-1.45], p = 0.34). Conclusions: Prasugrel and ticagrelor are superior to clopidogrel for ACS. Head-to-head comparison suggests similar efficacy and safety of prasugrel and ticagrelor, but prasugrel appears more protective from stent thrombosis, while causing more bleedings.

Original languageEnglish
Pages (from-to)325-331
Number of pages7
JournalInternational Journal of Cardiology
Volume150
Issue number3
DOIs
Publication statusPublished - Aug 4 2011

Fingerprint

Acute Coronary Syndrome
clopidogrel
Meta-Analysis
Odds Ratio
Hemorrhage
Stents
Thrombosis
Stroke
Myocardial Infarction
Prasugrel Hydrochloride
Ticagrelor
PubMed
Confidence Intervals
Safety
Pharmaceutical Preparations

Keywords

  • Acute coronary syndrome
  • Meta-analysis
  • Prasugrel
  • Ticagrelor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Biondi-Zoccai, G., Lotrionte, M., Agostoni, P., Abbate, A., Romagnoli, E., Sangiorgi, G., ... Sheiban, I. (2011). Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. International Journal of Cardiology, 150(3), 325-331. https://doi.org/10.1016/j.ijcard.2010.08.035

Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. / Biondi-Zoccai, Giuseppe; Lotrionte, Marzia; Agostoni, Pierfrancesco; Abbate, Antonio; Romagnoli, Enrico; Sangiorgi, Giuseppe; Angiolillo, Dominick J.; Valgimigli, Marco; Testa, Luca; Gaita, Fiorenzo; Sheiban, Imad.

In: International Journal of Cardiology, Vol. 150, No. 3, 04.08.2011, p. 325-331.

Research output: Contribution to journalArticle

Biondi-Zoccai, G, Lotrionte, M, Agostoni, P, Abbate, A, Romagnoli, E, Sangiorgi, G, Angiolillo, DJ, Valgimigli, M, Testa, L, Gaita, F & Sheiban, I 2011, 'Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes', International Journal of Cardiology, vol. 150, no. 3, pp. 325-331. https://doi.org/10.1016/j.ijcard.2010.08.035
Biondi-Zoccai, Giuseppe ; Lotrionte, Marzia ; Agostoni, Pierfrancesco ; Abbate, Antonio ; Romagnoli, Enrico ; Sangiorgi, Giuseppe ; Angiolillo, Dominick J. ; Valgimigli, Marco ; Testa, Luca ; Gaita, Fiorenzo ; Sheiban, Imad. / Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. In: International Journal of Cardiology. 2011 ; Vol. 150, No. 3. pp. 325-331.
@article{2f153602495c406e957de5356f8827e9,
title = "Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes",
abstract = "Background: Clopidogrel is beneficial after ACS. Recent data suggest the superiority of prasugrel or ticagrelor compared with clopidogrel. However, there is no comparison of prasugrel vs. ticagrelor. We performed an adjusted indirect meta-analysis comparing prasugrel vs. ticagrelor for acute coronary syndromes (ACSs). Methods: Randomized trials were searched in PubMed. The primary end-point was the composite of death, myocardial infarction (MI) or stroke. Odds ratios (OR) were computed (95{\%} confidence intervals). Results: Three trial (32,893) patients were included. Overall, either prasugrel or ticagrelor appeared significantly superior to clopidogrel for the 12-month risk of death, MI or stroke (OR = 0.83 [0.77-0.89], p <0.001), death (OR = 0.83 [0.74-0.93], p = 0.001), MI (OR = 0.79 [0.73-0.86], p <0.001), and stent thrombosis (OR = 0.61 [0.51-0.74], p <0.001), without any significant difference in stroke or major bleeding (both p > 0.05), despite more frequent drug discontinuation (OR = 1.12 [1.05-1.19], p <0.001). Head-to-head comparison of prasugrel vs. ticagrelor showed no significant differences in overall death, MI, stroke, or their composite (all p > 0.05). Prasugrel was associated with a significantly lower risk of stent thrombosis (OR = 0.64 [0.43-0.93], p = 0.020). Ticagrelor was associated with a significantly lower risk of any major bleeding (OR = 1.43 [1.10-1.85], p = 0.007), and major bleeding associated with bypass grafting (OR = 4.30 [1.73-10.6], p = 0.002). However, the more clinically relevant risk of major bleeding not related to bypass surgery was similar with either prasugrel or ticagrelor (OR = 1.06 [0.77-1.45], p = 0.34). Conclusions: Prasugrel and ticagrelor are superior to clopidogrel for ACS. Head-to-head comparison suggests similar efficacy and safety of prasugrel and ticagrelor, but prasugrel appears more protective from stent thrombosis, while causing more bleedings.",
keywords = "Acute coronary syndrome, Meta-analysis, Prasugrel, Ticagrelor",
author = "Giuseppe Biondi-Zoccai and Marzia Lotrionte and Pierfrancesco Agostoni and Antonio Abbate and Enrico Romagnoli and Giuseppe Sangiorgi and Angiolillo, {Dominick J.} and Marco Valgimigli and Luca Testa and Fiorenzo Gaita and Imad Sheiban",
year = "2011",
month = "8",
day = "4",
doi = "10.1016/j.ijcard.2010.08.035",
language = "English",
volume = "150",
pages = "325--331",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes

AU - Biondi-Zoccai, Giuseppe

AU - Lotrionte, Marzia

AU - Agostoni, Pierfrancesco

AU - Abbate, Antonio

AU - Romagnoli, Enrico

AU - Sangiorgi, Giuseppe

AU - Angiolillo, Dominick J.

AU - Valgimigli, Marco

AU - Testa, Luca

AU - Gaita, Fiorenzo

AU - Sheiban, Imad

PY - 2011/8/4

Y1 - 2011/8/4

N2 - Background: Clopidogrel is beneficial after ACS. Recent data suggest the superiority of prasugrel or ticagrelor compared with clopidogrel. However, there is no comparison of prasugrel vs. ticagrelor. We performed an adjusted indirect meta-analysis comparing prasugrel vs. ticagrelor for acute coronary syndromes (ACSs). Methods: Randomized trials were searched in PubMed. The primary end-point was the composite of death, myocardial infarction (MI) or stroke. Odds ratios (OR) were computed (95% confidence intervals). Results: Three trial (32,893) patients were included. Overall, either prasugrel or ticagrelor appeared significantly superior to clopidogrel for the 12-month risk of death, MI or stroke (OR = 0.83 [0.77-0.89], p <0.001), death (OR = 0.83 [0.74-0.93], p = 0.001), MI (OR = 0.79 [0.73-0.86], p <0.001), and stent thrombosis (OR = 0.61 [0.51-0.74], p <0.001), without any significant difference in stroke or major bleeding (both p > 0.05), despite more frequent drug discontinuation (OR = 1.12 [1.05-1.19], p <0.001). Head-to-head comparison of prasugrel vs. ticagrelor showed no significant differences in overall death, MI, stroke, or their composite (all p > 0.05). Prasugrel was associated with a significantly lower risk of stent thrombosis (OR = 0.64 [0.43-0.93], p = 0.020). Ticagrelor was associated with a significantly lower risk of any major bleeding (OR = 1.43 [1.10-1.85], p = 0.007), and major bleeding associated with bypass grafting (OR = 4.30 [1.73-10.6], p = 0.002). However, the more clinically relevant risk of major bleeding not related to bypass surgery was similar with either prasugrel or ticagrelor (OR = 1.06 [0.77-1.45], p = 0.34). Conclusions: Prasugrel and ticagrelor are superior to clopidogrel for ACS. Head-to-head comparison suggests similar efficacy and safety of prasugrel and ticagrelor, but prasugrel appears more protective from stent thrombosis, while causing more bleedings.

AB - Background: Clopidogrel is beneficial after ACS. Recent data suggest the superiority of prasugrel or ticagrelor compared with clopidogrel. However, there is no comparison of prasugrel vs. ticagrelor. We performed an adjusted indirect meta-analysis comparing prasugrel vs. ticagrelor for acute coronary syndromes (ACSs). Methods: Randomized trials were searched in PubMed. The primary end-point was the composite of death, myocardial infarction (MI) or stroke. Odds ratios (OR) were computed (95% confidence intervals). Results: Three trial (32,893) patients were included. Overall, either prasugrel or ticagrelor appeared significantly superior to clopidogrel for the 12-month risk of death, MI or stroke (OR = 0.83 [0.77-0.89], p <0.001), death (OR = 0.83 [0.74-0.93], p = 0.001), MI (OR = 0.79 [0.73-0.86], p <0.001), and stent thrombosis (OR = 0.61 [0.51-0.74], p <0.001), without any significant difference in stroke or major bleeding (both p > 0.05), despite more frequent drug discontinuation (OR = 1.12 [1.05-1.19], p <0.001). Head-to-head comparison of prasugrel vs. ticagrelor showed no significant differences in overall death, MI, stroke, or their composite (all p > 0.05). Prasugrel was associated with a significantly lower risk of stent thrombosis (OR = 0.64 [0.43-0.93], p = 0.020). Ticagrelor was associated with a significantly lower risk of any major bleeding (OR = 1.43 [1.10-1.85], p = 0.007), and major bleeding associated with bypass grafting (OR = 4.30 [1.73-10.6], p = 0.002). However, the more clinically relevant risk of major bleeding not related to bypass surgery was similar with either prasugrel or ticagrelor (OR = 1.06 [0.77-1.45], p = 0.34). Conclusions: Prasugrel and ticagrelor are superior to clopidogrel for ACS. Head-to-head comparison suggests similar efficacy and safety of prasugrel and ticagrelor, but prasugrel appears more protective from stent thrombosis, while causing more bleedings.

KW - Acute coronary syndrome

KW - Meta-analysis

KW - Prasugrel

KW - Ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=79960555699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960555699&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2010.08.035

DO - 10.1016/j.ijcard.2010.08.035

M3 - Article

C2 - 20828843

AN - SCOPUS:79960555699

VL - 150

SP - 325

EP - 331

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -